Pharmaceutical Intermediates Market Size
|Fastest Growing Market:||Asia Pacific|
|Largest Market:||North America|
*Disclaimer: Major Players sorted in no particular order
Need a report that reflects how COVID-19 has impacted this market and it's growth?
Pharmaceutical Intermediates Market Analysis
The pharmaceutical intermediates market studied is anticipated to grow with a CAGR of nearly 5.3%, during the forecast period.
COVID-19 pandemic had a significant impact on the market studied. According to a study that was published in the American Chemical Society Pharmacology and Translational Science, 2020, new potential therapeutics for COVID-19 were discovered using a combined virtual and experimental screening strategy. Furthermore, they choose among the medications that were already in use and were examined to check for structural similarity against a library of almost 4,000 medications that were already in use, with hydroxychloroquine (HCQ) serving as a reference medication. The study suggested remdesivir and favipiravir therapies as prospective adjuvants in COVID-19 treatment and zuclopenthixol, nebivolol, and amodiaquine as potential candidates for clinical trials against the early phase of the SARS-CoV-2 infection. Thus, the pharmaceutical intermediates market witnessed significant growth during the covid pandemic and it is observed that even after the pandemic, the demand for pharmaceutical intermediates is high in the global market.
Specific factors that are driving the market growth include the increasing prevalence of chronic diseases and growing R&D initiatives and activities in the pharmaceutical industry. Given that these pharma intermediates are used in the treatment of cancer detection and a variety of chronic diseases, the rise in the prevalence of chronic diseases is projected to propel market expansion in the area under study. For instance, chronic diseases account for around 41 million annual fatalities, or 71% of all fatalities worldwide, according to the WHO's key facts on non-communicable diseases published in April 2021. The high fatality rate from these diseases increases the demand for early intervention, which in turn propels the market's expansion.
The market is expected to develop due to the rising prevalence of respiratory ailments such as lung cancer, chronic obstructive pulmonary diseases, and others. For instance, the WHO stated in its January 2022 report that Chronic Obstructive Pulmonary Disease (COPD) is the 3rd most common cause of morbidity and mortality globally. Low- and middle-income nations (LMIC) countries contribute largely to the global rise in prevalence of COPD. The necessity for effective treatment of the disease is brought on by the increasing prevalence of chronic obstructive pulmonary disease which is expected to increase the market growth.
There has been an upsurge in the usage of advanced technologies, such as high throughput, bioinformatics, and combinatorial chemistry for better drug candidate identification. The discovery and development of novel drugs to treat, prevent, or cure several diseases, including cancer, diabetes, cardiovascular disorders, and chronic kidney disease, has been accelerated by the significant rise in disease incidence rates around the world. The United States health care spending climbed 9.7% to reach USD 4.3 trillion in 2021, a substantially greater rate than the 4.2% increase recorded in 2020, according to the CMS data published in March 2022. Additionally, increased investments in R&D are a significant driver of market expansion. For instance, JSR life sciences introduced a corporate venture fund in March 2021 with a focus on small and developing biotech, attracting clients to its range of life sciences services. Hence, owing to the rising R&D activities in the pharmaceutical industry, the usage of pharmaceutical intermediates is expected to observe strong growth as well.
However, stringent regulatory issues regarding certain pharmaceutical intermediate substances are expected to hinder market growth.
Pharmaceutical Intermediates Industry Segmentation
As per the scope of the report, pharmaceutical intermediates are the drugs used as raw materials for the production of bulk drugs, or they can refer to a material produced during the synthesis of an API that must undergo further molecular change or processing before it becomes an API. The Pharmaceutical Intermediates Market is Segmented by Type (Chemical Intermediate, Bulk Drug Intermediate, and Others), Application (Analgesics, Anti-Infective Drugs, Cardiovascular Drugs, Oral Antidiabetic Drugs, Antimicrobial Drugs, and Others), End-User (Biotech and Pharma Companies, Research Institutions, and Others), and Geography (North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions, globally. The report offers the value (in USD million) for the above segments.
|Bulk Drug Intermediate|
|Oral Antidiabetic Drugs|
|Biotech and Pharma Companies|
Pharmaceutical Intermediates Market Trends
This section covers the major market trends shaping the Pharmaceutical Intermediates Market according to our research experts:
Cardiovascular Drugs Hold Significant Share in the Global Pharmaceutical Intermediates Market
The burden of heart disease on the global healthcare system is on the rise. One of the main elements driving the market expansion of pharmaceutical intermediates is the increase in the incidence of chronic cardiovascular disorders such as heart failure and coronary artery diseases. Ischemic heart disease (IHD) is a primary cause of death worldwide, according to a report published in the Cureus Journal of Medical Science in July 2021. The same report stated that around 126 million people worldwide (1,655 per 100,000), or roughly 1.72% of the world's population are affected by ischemic heart disease. By 2030, it is anticipated that there would be more than 1,845 cases of ischemic heart disease per 100,000 people worldwide.
Furthermore, risk factors associated with heart disease are on the rise across several countries which is boosting the prevalence. For instance, as of the year 2022, around 11.10% of men and 3.10% of women in France are alcoholics, as per the data from World Population Review. As alcoholism increases the chances of heart disease, it has a significant impact on market growth. Similarly, the UK Factsheet by the British Heart Foundation, released in July 2021, estimated that 7.6 million people in the United Kingdom were affected by heart and circulation disorders. Additionally, according to the same source, heart and circulation illnesses are responsible for more than 1,60,000 deaths annually in the United Kingdom, or 25% of all fatalities in the country. This high prevalence of cardiovascular diseases is generating a huge demand for cardiovascular drugs, which, in turn, is expected to propel the growth in the need for various pharmaceutical intermediates.
Hence, owing to the aforementioned factors, the concerned segment of the pharmaceutical intermediates market is expected to observe steady growth over the forecast period.
To understand key trends, Download Sample Report
North America Dominates the Global Pharmaceutical Intermediates Market
North America dominates the Pharmaceutical Intermediates products market primarily due to the advanced research and development facilities mainly across the United States and Canada. In addition, the rising prevalence of various chronic conditions is also fueling market growth across the region.
Growing government support for healthcare in the United States is one element contributing to the market's expansion in that country. For instance, the National Institutes of Health (NIH) received more than USD 700 billion in public funding over the past few decades, according to a 2021 study from the Congressional Budget Office. Six grants were given out by the Food and Drug Administration (FDA) in 2020 to fund new clinical trials and advance the creation of pharmaceuticals for the treatment of uncommon diseases. The need for pharmaceutical intermediates, which are widely used in the drug discovery process, will increase as a result. According to "clinicaltrials.gov," there were 443,207 registered clinical studies in the United States as of November 2022. Similarly, according to ClinicalTrial.gov, Canadian pharmaceutical companies and research institutions have strong R&D pipelines as of the year 2022. Of the 5,659 new studies in the pipeline at that time that were in various stages of evaluation, 1,397 (24%) were in Phase III clinical trials that had received the Food and Drug Administration (FDA) or European Medicines Evaluation Agency (EMA) approval, covering a wide range of therapeutic areas.
As infectious diseases become more widespread, attention is being paid more and more to their diagnosis and treatment. The Centers for Disease Control and Prevention (CDC) estimated that in 2020, there were approximately 7,174 tuberculosis cases discovered in the United States, translating to a rate of 2.2 per 100,000 people. Thus, a high prevalence of tuberculosis patients drives up the demand for therapy, which in turn drives the market for pharmaceutical intermediates. The CDC reported in a February 2022 article that each year in the United States, Salmonella bacteria causes around 1.35 million infections, 26,500 hospitalizations, and 420 fatalities. The nation's healthcare system is burdened by the large number of infectious infections that are reported each year. As a result, the market under study may experience growth due to the extraordinary rise in demand for treatments for these diseases. Thus, the abovementioned factors are expected to increase market growth.
To understand geography trends, Download Sample Report
Pharmaceutical Intermediates Industry Overview
The global pharmaceutical intermediates market is competitive and consists of a few major players. Companies like Aceto Corporation, BASF SE, Chiracon GmbH, Yin-sheng Bio-tech Co., Ltd., Dishman Group, Green Vision Life Sciences, Codexis, Inc., Sanofi SAIS, Vertellus Holdings LLC., among others, hold the substantial market share in the market.
Pharmaceutical Intermediates Market Leaders
*Disclaimer: Major Players sorted in no particular order
Pharmaceutical Intermediates Market News
- In March 2022, Sumitomo Chemical Co., Ltd. announced that it will construct a new manufacturing plant for active pharmaceutical ingredients (APIs) and intermediates for small molecule drugs at its Oita Works (Oita City, Oita Prefecture, Japan). This project is to enhance the Company’s capacity to supply a variety of high-quality APIs and intermediates in response to the increasing demand for small-molecule drugs.
- In October 2022, AstraZeneca’s Imjudo (tremelimumab) in combination with Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with unresectable hepatocellular carcinoma (HCC), the most common type of liver cancer.
- In February 2022, three manufacturing facilities have been purchased by CordenPharma from Vifor Pharma. These facilities will eventually be renamed Corden Pharma Fribourg S.A. in Switzerland (with its branch in Ettingen) and Corden Pharma Lisbon S.A. in Portugal.
Pharmaceutical Intermediates Market Report - Table of Contents
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Growing R&D Initiatives and Activities in the Pharmaceutical Industry
4.3 Market Restraints
4.3.1 Stringent Regulatory Issues Regarding Certain Pharmaceutical Intermediate Substances
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value – USD million)
5.1 By Type
5.1.1 Chemical Intermediate
5.1.2 Bulk Drug Intermediate
5.2 By Application
5.2.2 Anti-Infective Drugs
5.2.3 Cardiovascular Drugs
5.2.4 Oral Antidiabetic Drugs
5.2.5 Antimicrobial Drugs
5.3 By End-User
5.3.1 Biotech and Pharma Companies
5.3.2 Research Institutions
5.4.1 North America
22.214.171.124 United States
126.96.36.199 United Kingdom
188.8.131.52 Rest of Europe
184.108.40.206 South Korea
220.127.116.11 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
18.104.22.168 South Africa
22.214.171.124 Rest of Middle-East and Africa
5.4.5 South America
126.96.36.199 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 A.R. Life Science
6.1.2 Aceto Corporation
6.1.3 BASF SE
6.1.4 Chiracon GmbH
6.1.5 Codexis, Inc.
6.1.6 Dishman Group
6.1.7 Green Vision Life Sciences
6.1.9 Midas Pharma GmbH
6.1.10 Sanofi SAIS
6.1.11 Vertellus Holdings LLC
6.1.12 Yin-sheng Bio-tech Co., Ltd.
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Pharmaceutical Intermediates Market Research FAQs
What is the study period of this market?
The Pharmaceutical Intermediates Market is studied from 2019 - 2027.
What is the growth rate of Pharmaceutical Intermediates Market?
The Pharmaceutical Intermediates Market is growing at a CAGR of 5.3% over the next 5 years.
Which region has highest growth rate in Pharmaceutical Intermediates Market?
Asia Pacific is growing at the highest CAGR over 2019-2027.
Which region has largest share in Pharmaceutical Intermediates Market?
North America holds highest share in 2021.
Who are the key players in Pharmaceutical Intermediates Market?
Chiracon GmbH , BASF SE, Sanofi SAIS, Aceto, Codexis, Inc. are the major companies operating in Pharmaceutical Intermediates Market.
Pharmaceutical Intermediates Industry Report
Statistics for the 2023 Pharmaceutical Intermediates market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Pharmaceutical Intermediates analysis includes a market forecast outlook to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.